D.E. Shaw & Co
ACOR

D.E. Shaw & Co’s Acorda Therapeutics ACOR Stock Holding History

D.E. Shaw & Co’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-137
Closed -$12K – 4272
2020
Q2 		$12K Hold
137
– – ﹤0.01% 3944
2020
Q1 		$15K Sell
137
-998
-88% -$196K ﹤0.01% 3861
2019
Q4 		$278K Sell
1,135
-149
-12% -$37.6K ﹤0.01% 3662
2019
Q3 		$442K Sell
1,284
-1,638
-56% -$890K ﹤0.01% 3268
2019
Q2 		$2.69M Buy
2,922
+1,406
+93% +$1.73M ﹤0.01% 2029
2019
Q1 		$2.42M Sell
1,516
-565
-27% -$1.02M ﹤0.01% 2026
2018
Q4 		$3.89M Sell
2,081
-1,203
-37% -$2.62M 0.01% 1678
2018
Q3 		$7.75M Sell
3,284
-1,432
-30% -$4.43M 0.01% 1273
2018
Q2 		$16.2M Buy
4,716
+1,631
+53% +$4.99M 0.02% 837
2018
Q1 		$8.75M Sell
3,085
-1,680
-35% -$5.03M 0.01% 1074
2017
Q4 		$12.3M Buy
4,765
+66
+1% +$188K 0.02% 914
2017
Q3 		$13.3M Sell
4,699
-457
-9% -$1.2M 0.02% 777
2017
Q2 		$12.2M Buy
5,156
+1,476
+40% +$2.92M 0.02% 803
2017
Q1 		$9.27M Sell
3,680
-2,099
-36% -$6.04M 0.02% 929
2016
Q4 		$13M Buy
5,779
+198
+4% +$471K 0.02% 813
2016
Q3 		$14M Buy
5,581
+1,016
+22% +$3.03M 0.02% 723
2016
Q2 		$14M Buy
4,565
+19
+0.4% +$61.8K 0.03% 705
2016
Q1 		$14.4M Buy
4,546
+3,113
+217% +$12.9M 0.03% 671
2015
Q4 		$7.36M Buy
1,433
+1,184
+476% +$5.17M 0.01% 1155
2015
Q3 		$794K Buy
249
+167
+204% +$648K ﹤0.01% 2754
2015
Q2 		$326K Sell
82
-122
-60% -$471K ﹤0.01% 3381
2015
Q1 		$813K Buy
204
+8
+4% +$36.6K ﹤0.01% 2725
2014
Q4 		$959K Sell
196
-357
-65% -$1.53M ﹤0.01% 2859
2014
Q3 		$2.25M Buy
+553
New +$2.07M ﹤0.01% 2152
2014
Q1 		– Sell
-105
Closed -$368K – 4723
2013
Q4 		$368K Buy
+105
New +$409K ﹤0.01% 3929

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co's ACOR Position: Q3 2020 in Review

D.E. Shaw & Co sold out of Acorda Therapeutics (ACOR) in Q3 2020, closing a stake of 137 shares — an estimated $12K sold.

D.E. Shaw & Co first reported a position in ACOR in Q4 2013 and held it in 25 quarters. The position peaked at $16.2M in Q2 2018. 60 funds tracked by Wall St. Rank hold ACOR as of Q3 2020.

  • D.E. Shaw & Co reported no remaining Acorda Therapeutics position as of Q3 2020 after selling out during the quarter.
  • D.E. Shaw & Co sold 137 Acorda Therapeutics shares in Q3 2020, an estimated $12K.
  • D.E. Shaw & Co first reported a position in Acorda Therapeutics in Q4 2013 and held it in 25 quarters.
  • D.E. Shaw & Co's Acorda Therapeutics position peaked at $16.2M in Q2 2018.
  • 60 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2020.

Based on D.E. Shaw & Co's 13F filing for Q3 2020, filed 16 Nov 2020.